130 related articles for article (PubMed ID: 1748396)
21. Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; Smith TL; Cortes J; Giles FJ; Rios MB; Mallard S; Gajewski J; Murgo A; Cheson B; O'Brien S
J Clin Oncol; 2000 Oct; 18(20):3513-21. PubMed ID: 11032593
[TBL] [Abstract][Full Text] [Related]
22. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
[TBL] [Abstract][Full Text] [Related]
23. Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Bolaman Z; Köseoğlu M; Ayyildiz O; Kadiköylü G; Sönmez HM; Demir S; Müftüoğlu E
Haematologia (Budap); 2002; 32(1):49-57. PubMed ID: 12243555
[TBL] [Abstract][Full Text] [Related]
24. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
[TBL] [Abstract][Full Text] [Related]
25. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
[TBL] [Abstract][Full Text] [Related]
27. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
Kantarjian HM; Walters RS; Keating MJ; Talpaz M; Andersson B; Beran M; McCredie KB; Freireich EJ
Cancer; 1988 Aug; 62(4):672-6. PubMed ID: 3165046
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Dutcher JP; Eudey L; Wiernik PH; Paietta E; Bennett JM; Arlin Z; Kellermeyer R; Rowe J; O'Connell M; Oken M
Leukemia; 1992 Aug; 6(8):770-5. PubMed ID: 1379312
[TBL] [Abstract][Full Text] [Related]
29. Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).
Tedeschi A; Montillo M; Ferrara F; Nosari A; Mele G; Copia C; Leoni P; Morra E
Eur J Haematol; 2000 Mar; 64(3):182-7. PubMed ID: 10997884
[TBL] [Abstract][Full Text] [Related]
30. Extramedullary blast crisis in chronic myeloid leukemia.
Specchia G; Palumbo G; Pastore D; Mininni D; Mestice A; Liso V
Leuk Res; 1996; 20(11-12):905-8. PubMed ID: 9009247
[TBL] [Abstract][Full Text] [Related]
31. Sequential hydroxyurea-cytarabine chemotherapy for refractory non-Hodgkin's lymphoma.
Schilsky RL; Williams SF; Ultmann JE; Watson S
J Clin Oncol; 1987 Mar; 5(3):419-25. PubMed ID: 3819808
[TBL] [Abstract][Full Text] [Related]
32. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
Montefusco E; Petti MC; Alimena G; Latagliata R; Celesti F; Capria S; Amadori S; Avvisati G; Mandelli F
Ann Oncol; 1997 Feb; 8(2):175-9. PubMed ID: 9093727
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon alpha and hydroxyurea: a novel approach.
Jehn U; Pötscher C; Heinemann V
Leuk Lymphoma; 1995 Sep; 19(1-2):153-7. PubMed ID: 8574162
[TBL] [Abstract][Full Text] [Related]
34. Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.
Marsh JH; Kreis W; Barile B; Akerman S; Schulman P; Allen SL; DeMarco LC; Schuster MW; Budman DR
Cancer Chemother Pharmacol; 1993; 31(6):481-4. PubMed ID: 8453688
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
Grant S; Baker M; Bhalla K
Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
[TBL] [Abstract][Full Text] [Related]
36. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
37. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
[TBL] [Abstract][Full Text] [Related]
38. Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.
Kantarjian HM; Vellekoop L; McCredie KB; Keating MJ; Hester J; Smith T; Barlogie B; Trujillo J; Freireich EJ
J Clin Oncol; 1985 Feb; 3(2):192-200. PubMed ID: 3855444
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
Oki Y; Kantarjian HM; Gharibyan V; Jones D; O'brien S; Verstovsek S; Cortes J; Morris GM; Garcia-Manero G; Issa JP
Cancer; 2007 Mar; 109(5):899-906. PubMed ID: 17236224
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
O'Brien S; Talpaz M; Cortes J; Shan J; Giles FJ; Faderl S; Thomas D; Garcia-Manero G; Mallard S; Beth M; Koller C; Kornblau S; Andreeff M; Murgo A; Keating M; Kantarjian HM
Cancer; 2002 Apr; 94(7):2024-32. PubMed ID: 11932905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
